Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

NCT03257358 ·Status: COMPLETED ·Phase: PHASE4

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT01310166 ·Status: COMPLETED ·Phase: PHASE4

Fingolimod Effect on Cytokine and Chemokine Levels

NCT02373098 ·Status: COMPLETED ·Phase: PHASE4

Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells

NCT01587690 ·Status: COMPLETED

Novel Imaging Markers in SPMS

NCT05357833 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

NCT06127095 ·Status: COMPLETED

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 ·Status: COMPLETED ·Phase: PHASE2

Cellular microRNA Signatures in Multiple Sclerosis

NCT05290688 ·Status: UNKNOWN ·Phase: NA

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

NCT05663853 ·Status: COMPLETED

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

NCT01281657 ·Status: COMPLETED

A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

NCT05081700 ·Status: COMPLETED

Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis

NCT04892134 ·Status: RECRUITING

Measuring Active Microglia in Progressive Multiple Sclerosis

NCT02207075 ·Status: COMPLETED

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

NCT01592097 ·Status: COMPLETED

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

NCT01539395 ·Status: WITHDRAWN

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

NCT01199861 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

NCT02325440 ·Status: UNKNOWN ·Phase: PHASE4

Evaluation of the Microbiome in Multiple Sclerosis

NCT05844826 ·Status: TERMINATED ·Phase: NA

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

NCT01541618 ·Status: COMPLETED

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis

NCT01755871 ·Status: TERMINATED ·Phase: PHASE4

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

NCT05121662 ·Status: COMPLETED

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

NCT01127750 ·Status: COMPLETED ·Phase: PHASE3

Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2

NCT06309173 ·Status: WITHDRAWN

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01395316 ·Status: COMPLETED ·Phase: PHASE4

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

NCT01737372 ·Status: COMPLETED